Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma.
Pneumococcal vaccine [heptadecavalent types 1, 2, 3, 4, 6A, 7F, 8, 9N, 11A, 12F, 14, 15F, 17F, 18C, 19F, 23F and 25 pneumococcal capsular polysaccharide vaccine (Moniarix)] or placebo were evaluated in 26 and 21 patients with bronchogenic carcinoma, most of whom did not receive prior radiotherapy or chemotherapy. No difference was detected as far as clinical outcome is concerned: 3 vaccinated patients out of 26 (11.5%) developed pneumococcal infections (1 fatal bacteremia) and 4/21 (19%) of those who received a placebo presented such an infection (1 fatal bacteremia). The antibody response was significantly increased in the vaccines for types 1, 2, 7F, 8, 9N, 12F, 14, 17F, 18C, 23F and 25.
D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D002283:Carcinoma, Bronchogenic / Q000276:immunology* / Q000628:therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000517:prevention & control*; D013296:Streptococcus pneumoniae / Q000276:immunology; D014611:Vaccination
D000907:Antibodies, Bacterial